{"name":"Jiangsu Province Centers for Disease Control and Prevention","slug":"jiangsu-province-centers-for-disease-control-and-prevention","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"oncology","drugs":[{"name":"SYS6006","genericName":"SYS6006","slug":"sys6006","indication":"Other","status":"marketed"},{"name":"Attenuated Hepatitis A Vaccine, H2 Strain","genericName":"Attenuated Hepatitis A Vaccine, H2 Strain","slug":"attenuated-hepatitis-a-vaccine-h2-strain","indication":"Other","status":"marketed"},{"name":"Recombinant SARS-CoV-2 Ad5 vectored vaccine","genericName":"Recombinant SARS-CoV-2 Ad5 vectored vaccine","slug":"recombinant-sars-cov-2-ad5-vectored-vaccine","indication":"Other","status":"marketed"},{"name":"Standard dosage inactivated vaccine","genericName":"Standard dosage inactivated vaccine","slug":"standard-dosage-inactivated-vaccine","indication":"Other","status":"marketed"},{"name":"A+C Vaccine","genericName":"A+C Vaccine","slug":"a-c-vaccine","indication":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C","status":"marketed"},{"name":"A+C+hib Conjugate Vaccine","genericName":"A+C+hib Conjugate Vaccine","slug":"a-c-hib-conjugate-vaccine","indication":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C","status":"phase_3"},{"name":"Ad5-nCoV-IH","genericName":"Ad5-nCoV-IH","slug":"ad5-ncov-ih","indication":"Other","status":"marketed"},{"name":"Ad5-nCoV-IM","genericName":"Ad5-nCoV-IM","slug":"ad5-ncov-im","indication":"Other","status":"marketed"},{"name":"Aerosolized Ad5-nCoV","genericName":"Aerosolized Ad5-nCoV","slug":"aerosolized-ad5-ncov","indication":"Other","status":"marketed"},{"name":"Changchun Werersai","genericName":"Changchun Werersai","slug":"changchun-werersai","indication":"Other","status":"phase_3"},{"name":"DTaP Vaccine A","genericName":"DTaP Vaccine A","slug":"dtap-vaccine-a","indication":"Prevention of diphtheria, tetanus, and pertussis in infants and children","status":"phase_3"},{"name":"DTaP Vaccine B","genericName":"DTaP Vaccine B","slug":"dtap-vaccine-b","indication":"Prevention of diphtheria, tetanus, and pertussis in infants and children","status":"phase_3"},{"name":"Double dosage inactivated vaccine","genericName":"Double dosage inactivated vaccine","slug":"double-dosage-inactivated-vaccine","indication":"Other","status":"marketed"},{"name":"Influenza virus split vaccine","genericName":"Influenza virus split vaccine","slug":"influenza-virus-split-vaccine","indication":"Prevention of influenza caused by virus strains included in the vaccine","status":"phase_2"},{"name":"Intranasal Influenza Live Attenuated Vaccine","genericName":"Intranasal Influenza Live Attenuated Vaccine","slug":"intranasal-influenza-live-attenuated-vaccine","indication":"Influenza prevention in children and adults","status":"marketed"},{"name":"Placebo Comparator: Placebo control","genericName":"Placebo Comparator: Placebo control","slug":"placebo-comparator-placebo-control","indication":"Other","status":"phase_3"},{"name":"Positive control vaccine 1","genericName":"Positive control vaccine 1","slug":"positive-control-vaccine-1","indication":"Positive control comparator in phase 3 clinical trials (specific indication not disclosed)","status":"phase_3"},{"name":"Positive control vaccine 2","genericName":"Positive control vaccine 2","slug":"positive-control-vaccine-2","indication":"Clinical trial positive control (specific indication unknown)","status":"phase_3"},{"name":"batch 2 of Ad5-nCoV","genericName":"batch 2 of Ad5-nCoV","slug":"batch-2-of-ad5-ncov","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Intramuscularly administered Ad5-nCoV vaccine","genericName":"Intramuscularly administered Ad5-nCoV vaccine","slug":"intramuscularly-administered-ad5-ncov-vaccine","indication":"COVID-19 prevention in adults","status":"marketed"},{"name":"batch 3 of Ad5-nCoV","genericName":"batch 3 of Ad5-nCoV","slug":"batch-3-of-ad5-ncov","indication":"COVID-19 prevention","status":"marketed"},{"name":"23vPPV+TIV","genericName":"23vPPV+TIV","slug":"23vppv-tiv","indication":"Prevention of pneumococcal disease caused by 23 serotypes of Streptococcus pneumoniae","status":"marketed"},{"name":"Active Comparator hepatitis B vaccine","genericName":"Active Comparator hepatitis B vaccine","slug":"active-comparator-hepatitis-b-vaccine","indication":"Prevention of hepatitis B infection","status":"phase_3"},{"name":"Inactivated SARS-CoV-2 vaccine","genericName":"Inactivated SARS-CoV-2 vaccine","slug":"inactivated-sars-cov-2-vaccine","indication":"Prevention of COVID-19 in adults and adolescents","status":"phase_3"},{"name":"batch 1 of Ad5-nCoV","genericName":"batch 1 of Ad5-nCoV","slug":"batch-1-of-ad5-ncov","indication":"COVID-19 prevention","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Experimental recombinant hepatitis B vaccine","genericName":"Experimental recombinant hepatitis B vaccine","slug":"experimental-recombinant-hepatitis-b-vaccine","indication":"Prevention of hepatitis B infection in unvaccinated or non-immune populations","status":"phase_3"},{"name":"Jilin Maifeng","genericName":"Jilin Maifeng","slug":"jilin-maifeng","indication":"Immune support and respiratory health (Phase 3 indication not fully specified in available data)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"H. pylori vaccine","genericName":"H. pylori vaccine","slug":"h-pylori-vaccine","indication":"Prevention of Helicobacter pylori infection","status":"phase_3"}]}],"pipeline":[{"name":"SYS6006","genericName":"SYS6006","slug":"sys6006","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Attenuated Hepatitis A Vaccine, H2 Strain","genericName":"Attenuated Hepatitis A Vaccine, H2 Strain","slug":"attenuated-hepatitis-a-vaccine-h2-strain","phase":"marketed","mechanism":"The Attenuated Hepatitis A Vaccine, H2 Strain, works by introducing a live, weakened form of the hepatitis A virus to stimulate an immune response.","indications":[],"catalyst":""},{"name":"Intramuscularly administered Ad5-nCoV vaccine","genericName":"Intramuscularly administered Ad5-nCoV vaccine","slug":"intramuscularly-administered-ad5-ncov-vaccine","phase":"marketed","mechanism":"An adenovirus type 5 (Ad5) vector vaccine delivers the SARS-CoV-2 spike protein gene intramuscularly to stimulate cellular and humoral immune responses against COVID-19.","indications":["COVID-19 prevention in adults"],"catalyst":""},{"name":"Recombinant SARS-CoV-2 Ad5 vectored vaccine","genericName":"Recombinant SARS-CoV-2 Ad5 vectored vaccine","slug":"recombinant-sars-cov-2-ad5-vectored-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Standard dosage inactivated vaccine","genericName":"Standard dosage inactivated vaccine","slug":"standard-dosage-inactivated-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"batch 3 of Ad5-nCoV","genericName":"batch 3 of Ad5-nCoV","slug":"batch-3-of-ad5-ncov","phase":"marketed","mechanism":"Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"23vPPV+TIV","genericName":"23vPPV+TIV","slug":"23vppv-tiv","phase":"marketed","mechanism":"A combined pneumococcal and influenza vaccine that stimulates immune responses against 23 serotypes of Streptococcus pneumoniae and seasonal influenza virus strains.","indications":["Prevention of pneumococcal disease caused by 23 serotypes of Streptococcus pneumoniae","Prevention of seasonal influenza"],"catalyst":""},{"name":"A+C Vaccine","genericName":"A+C Vaccine","slug":"a-c-vaccine","phase":"marketed","mechanism":"A+C Vaccine is a combined meningococcal vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C.","indications":["Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C"],"catalyst":""},{"name":"A+C+hib Conjugate Vaccine","genericName":"A+C+hib Conjugate Vaccine","slug":"a-c-hib-conjugate-vaccine","phase":"phase_3","mechanism":"A conjugate vaccine that combines antigens from meningococcus serogroups A and C with Haemophilus influenzae type b (Hib) to stimulate immune responses against these bacterial pathogens.","indications":["Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C","Prevention of invasive Haemophilus influenzae type b disease"],"catalyst":""},{"name":"Active Comparator hepatitis B vaccine","genericName":"Active Comparator hepatitis B vaccine","slug":"active-comparator-hepatitis-b-vaccine","phase":"phase_3","mechanism":"A hepatitis B vaccine that stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen.","indications":["Prevention of hepatitis B infection"],"catalyst":""},{"name":"Ad5-nCoV-IH","genericName":"Ad5-nCoV-IH","slug":"ad5-ncov-ih","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad5-nCoV-IM","genericName":"Ad5-nCoV-IM","slug":"ad5-ncov-im","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Aerosolized Ad5-nCoV","genericName":"Aerosolized Ad5-nCoV","slug":"aerosolized-ad5-ncov","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Changchun Werersai","genericName":"Changchun Werersai","slug":"changchun-werersai","phase":"phase_3","mechanism":"Changchun Werersai's mechanism of action is currently unknown.","indications":[],"catalyst":""},{"name":"DTaP Vaccine A","genericName":"DTaP Vaccine A","slug":"dtap-vaccine-a","phase":"phase_3","mechanism":"DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.","indications":["Prevention of diphtheria, tetanus, and pertussis in infants and children"],"catalyst":""},{"name":"DTaP Vaccine B","genericName":"DTaP Vaccine B","slug":"dtap-vaccine-b","phase":"phase_3","mechanism":"DTaP Vaccine B stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, and pertussis pathogens.","indications":["Prevention of diphtheria, tetanus, and pertussis in infants and children"],"catalyst":""},{"name":"Double dosage inactivated vaccine","genericName":"Double dosage inactivated vaccine","slug":"double-dosage-inactivated-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Experimental recombinant hepatitis B vaccine","genericName":"Experimental recombinant hepatitis B vaccine","slug":"experimental-recombinant-hepatitis-b-vaccine","phase":"phase_3","mechanism":"This recombinant hepatitis B vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against hepatitis B infection.","indications":["Prevention of hepatitis B infection in unvaccinated or non-immune populations"],"catalyst":""},{"name":"H. pylori vaccine","genericName":"H. pylori vaccine","slug":"h-pylori-vaccine","phase":"phase_3","mechanism":"This vaccine stimulates the immune system to recognize and eliminate Helicobacter pylori bacteria, preventing infection and associated gastric diseases.","indications":["Prevention of Helicobacter pylori infection","Prevention of H. pylori-associated peptic ulcer disease and gastric cancer"],"catalyst":""},{"name":"Inactivated SARS-CoV-2 vaccine","genericName":"Inactivated SARS-CoV-2 vaccine","slug":"inactivated-sars-cov-2-vaccine","phase":"phase_3","mechanism":"This inactivated vaccine trains the immune system to recognize and neutralize SARS-CoV-2 by presenting killed viral particles that cannot cause infection.","indications":["Prevention of COVID-19 in adults and adolescents"],"catalyst":""},{"name":"Influenza virus split vaccine","genericName":"Influenza virus split vaccine","slug":"influenza-virus-split-vaccine","phase":"phase_2","mechanism":"Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus.","indications":["Prevention of influenza caused by virus strains included in the vaccine"],"catalyst":""},{"name":"Intranasal Influenza Live Attenuated Vaccine","genericName":"Intranasal Influenza Live Attenuated Vaccine","slug":"intranasal-influenza-live-attenuated-vaccine","phase":"marketed","mechanism":"This live attenuated influenza vaccine stimulates immune responses by delivering weakened influenza virus strains intranasally to induce mucosal and systemic immunity.","indications":["Influenza prevention in children and adults"],"catalyst":""},{"name":"Jilin Maifeng","genericName":"Jilin Maifeng","slug":"jilin-maifeng","phase":"phase_3","mechanism":"Jilin Maifeng is a traditional Chinese medicine formulation designed to support immune function and respiratory health.","indications":["Immune support and respiratory health (Phase 3 indication not fully specified in available data)"],"catalyst":""},{"name":"Placebo Comparator: Placebo control","genericName":"Placebo Comparator: Placebo control","slug":"placebo-comparator-placebo-control","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism; it serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Positive control vaccine 1","genericName":"Positive control vaccine 1","slug":"positive-control-vaccine-1","phase":"phase_3","mechanism":"A positive control vaccine designed to elicit immune responses by presenting antigenic material to stimulate adaptive immunity.","indications":["Positive control comparator in phase 3 clinical trials (specific indication not disclosed)"],"catalyst":""},{"name":"Positive control vaccine 2","genericName":"Positive control vaccine 2","slug":"positive-control-vaccine-2","phase":"phase_3","mechanism":"A positive control vaccine designed to elicit immune responses as a reference standard in clinical trials.","indications":["Clinical trial positive control (specific indication unknown)"],"catalyst":""},{"name":"batch 1 of Ad5-nCoV","genericName":"batch 1 of Ad5-nCoV","slug":"batch-1-of-ad5-ncov","phase":"marketed","mechanism":"Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"batch 2 of Ad5-nCoV","genericName":"batch 2 of Ad5-nCoV","slug":"batch-2-of-ad5-ncov","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQUXVXSXZBMWZiN1pKWFhKRWhlMnJ2R1cxOTVVTEoxOVZLb0lfcm9iZjZYTkN5OU1uMG1QMVd3MHN2T2JVanR4OE96eGpoYXRjQWJFWWx1QkFWUllTSGFwY3o4WWN6YkpoTUl1MzhjN2Y5eVQxRmZMbGJsYjdnZkZNNkxZZHExeHg2YXF1RERGeDlzTi00d0E?oc=5","date":"2026-03-18","type":"trial","source":"Frontiers","summary":"Current status of vaccine clinical trials registered on China's Drug Trial Registration and information disclosure platform, 2013–2024 - Frontiers","headline":"Current status of vaccine clinical trials registered on China's Drug Trial Registration and information disclosure platf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1tc19pUkppOUt4ay1LR0MyampQeTdtMFVaTnRxMkEwcXFRM296eEpQYXNtWVc2WG5jY24yTi1tNm45X2JXekJwUlRIQlh4Z05EU1hVZFpoSTB1Vjc1bnlLSDV3?oc=5","date":"2025-12-03","type":"pipeline","source":"Global Times","summary":"17 provinces see high rates of influenza: China CDC - Global Times","headline":"17 provinces see high rates of influenza: China CDC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQVWhaZG5zU1dIMUNYWEFFcGtJc0FLMWlYR3RQTUVfU0MtNkdHR2xrVElqTTdaUnB4UmJTR1hRREVuRlA0dDhRT1lmMTllWnprYk5ZNjJWR0RYTTVHX1dMMURILVUxaEQ1MGUzUjA5UTFBaGZlWmNiQVEwempaU2F4RU5JdW5kN2dKRzJ5aXFWU0VVQ3JmcUp1bHZIbVRsUXNaUkNDRWJJc2gzZXQ1azhHTU5IZHNWTnp4azVnb0lzaENsMldlM01lMk5QeVFBZUk0U0pBaVVvbDdtUjI3MGEtNGQxOXMzMVQxYWZBcXFadGMtSDUybE5kUXZ3?oc=5","date":"2025-11-12","type":"pipeline","source":"World Health Organization (WHO)","summary":"Scaling up TB preventive treatment in China - World Health Organization (WHO)","headline":"Scaling up TB preventive treatment in China - World Health Organization (WHO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPYXFrTG5IcEl3VHRtdDgtNERIMWpDSW9Kc3YtOF9uSG9pVFpaN0EwR0NvQmV2T0lxNzdTbmIycFVyVURMMjh5ZlItdG1FdWM1N194dlVDWmRWTTVQaW5fbEdSUXN6OUtDWmpDMGVZcUhoOFRqRnQtTjhjVEg3cjFxTi1STzQ4eFRqZjdNTjVhWFZXQk5vQ0ZWdExvUQ?oc=5","date":"2025-11-07","type":"trial","source":"Vision Times","summary":"China CDC Data Shows Flu Cases Skyrocketing 87-Fold Week-Over-Week - Vision Times","headline":"China CDC Data Shows Flu Cases Skyrocketing 87-Fold Week-Over-Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9zRUxlRHZXWHF1dlBEemJvTV9XbDZnZFJ6cDVibTFfT3dLb0h5Njl4VjFYOE5MRWxHalRXOFlsRzVmdEhPbkp3M3JyaTlvTlE0Q3FpRHZmVV9JRTVXX0pr?oc=5","date":"2025-11-06","type":"pipeline","source":"nature.com","summary":"Mycobacterium tuberculosis transmission in China during the COVID-19 pandemic period (2020–2021) compared with the pre-pandemic period (2017–2019) - nature.com","headline":"Mycobacterium tuberculosis transmission in China during the COVID-19 pandemic period (2020–2021) compared with the pre-p","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE53TllqdWt4ZkRWaDNwcHVzakdMSlNGdDkxeWtqcmRTRHltZk1hYW9rZnh3dVZNWkhuU0ZOZ1VWdzNURElMaHpubjJDM1pOS3ZCaFB4REo1VkY0WWlQLTlJ?oc=5","date":"2025-08-15","type":"trial","source":"nature.com","summary":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial - nature.com","headline":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBzQS1xTHJ2ZVZwUkRjM2xlQV9mQzdSWW5sUXFaOVREQjc0Q1lMWHRDSnJHQ3BQMFhNUXVKeHBuWFJkZUtfRUJYYlM5XzBIa1JNWHd4S19BTDJod0Zwc29z?oc=5","date":"2025-07-01","type":"pipeline","source":"nature.com","summary":"Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1 - nature.com","headline":"Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPX0QyemNBVVdGUHd1c19sYjdoVDVYR3g5ZUlKcVBiVm5CVXU3bENiM1NBcFVseE9PWXVtME12ZkNpRE4xM1BpQnRwVG1hazJpWHJJVEYyczd0RjV6NC1ZVXFCQzlFd1JuS3d3dXcwZVhNamhnQms3VldpMnRfY2tHWkhUdnlSM1F4TDl3?oc=5","date":"2023-03-07","type":"regulatory","source":"The Lancet","summary":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open","headline":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac giv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5kdW1pckxJZEx0SkVKVEpPT0M1eWhVU2ZhUkFUMXNLamFSSmdLMENYRVZqU2ZLNVgxQnhoaHpVUTV3SUlvNm1oSGdXbVV4QnZZVGdseWpHX3hxcWotckRWMGhGWVk5Z3dvdHlram5qbTNxUkZa?oc=5","date":"2022-12-12","type":"trial","source":"Taylor & Francis Online","summary":"Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled tria","headline":"Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRXlKdHROT1NBRElhV0pvdi1hTUhoZENfTnRZZXJRRTFXR2FHaDZjNDgta3VPLV9DWVd3LUR3aEtrUjRicUE4T2Q2RHVhTjRCaUFhb0NUNFljd0xPMkhaT2N2TG5yQWRkT2c2R1h2cEUwOUJDZE4wb01DMzhkOHpQbmtvcHFsRUVobUF2eVhJbHNqeDJYZzFFbGJCb0daMldQTFlHMVZCeWZQM0ZwV3hXeVBNN2RHelAybVRzYW1FSzJUVlgxS3FkVHNPb0s5Qk12QkJXVXcyWQ?oc=5","date":"2021-04-18","type":"trial","source":"reuters.com","summary":"China trials mixing of CanSinoBIO's and Zhifei Longcom's COVID-19 vaccines -data - reuters.com","headline":"China trials mixing of CanSinoBIO's and Zhifei Longcom's COVID-19 vaccines -data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNTG5zbjBMOGd4NXlNWlFYX2FpMkY2elpyUXlJNG9Pb1FvaTV6WHJ2Z1llTS1ZX3ZEZk5FWHk0elE2MDVhaEFMMDdndEstUmhQWllUOGR4V3FGUWRLR2NIdjczNFZWZjFjWlZJbjJRSktGTnNtbkpPQjk3Ylh1N2VCZDMtektXNmJYU1R3?oc=5","date":"2020-05-22","type":"regulatory","source":"The Lancet","summary":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet","headline":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOekhjWHExTlg5WVBtRURJdlpuZkFoY0ZvTklXUGVpR1B0OWsxUERXSm9SaV9xUFRIR2dDQ0RJbkRLX21neTNRNmpDUUN3RUNzdlpCYkJHWVM2dHo0MDN0R1Z0emdWVGFlX2FoY3JvNzRRSFR5YWdzU3ptMllTZVRqWGNsZXhkWURJbFZCbGVJUmpITU9XRWc?oc=5","date":"2020-03-16","type":"pipeline","source":"Northeastern Global News","summary":"The global medical supply chain is not immune to COVID-19 - Northeastern Global News","headline":"The global medical supply chain is not immune to COVID-19","sentiment":"neutral"}],"patents":[],"drugCount":28,"phaseCounts":{"marketed":15,"phase_3":12,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}